Yazar "Kalyoncu, U." seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe AGREEMENT OF PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN ADULT ONSET STILL'S DISEASE(Bmj Publishing Group, 2016) Kalyoncu, U.; Kasifoglu, T.; Kisacik, B.; Oksuz, M. F.; Omma, A.; Bes, C.; Cinar, M.[Abstract Not Available]Öğe Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data(Clinical & Exper Rheumatology, 2021) Kimyon, G.; Kalyoncu, U.; Kiraz, S.; Bes, C.; Coskun, N.; Yagiz, B.; Kucuksahin, O.Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). Methods The TReasure database is a web-based, prospective, observational cohort of RA and spondyloarthritis patients from 17 centres in different regions of Turkey and data entry was enabled since December 2017. Until May 2019,2556 RA patients on biologic treatment were recorded. Demographic and RA-related data of 1526 patient either received LEF or MTX were compared, efficacy of both drugs compared by RA-disease activity composite indices. Reasons fordrug discontinuation also recorded. Drug retention rates were compared with Kaplan-Meier curves (log-rank test). Results Of 2556 RA patients 1526 (59.7%) were receiving concomitant LEE (n=646, 42 3%; median follow up 35 months) or concomitant MTX (n=880, 573%; median follow-up 32 months) at the time of initiation to their first bDMARDs. The LEE group were older and had longer disease duration, proportion of females and seropositive patients was higher in this group. In the LEE group, non-anti-TNF agents were used in higher rate. Remission rates, changes in composite indices and rate of comorbidities and adverse events were similar in both groups. The retention rate of LEE + non-anti-TNF b/tsDMARDs was higher compared to MTX + anti-TNF bDMARDs (p=0.002, log-rank). Rates of adverse events were similar in both groups. Conclusion LEE in combination with either anti TNF or non anti DIF drugs appears as an effective and safe therapeutic option at least as MIX.Öğe THE COMPARATIVE ONE-YEAR DRUG SURVIVAL RATE OF TUMOR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS; RESULTS FROM TURKBIO REGISTRY(Bmj Publishing Group, 2014) Sari, I.; Kalyoncu, U.; Onat, A. M.; Pamuk, O. N.; Karadag, O.; Kisacik, B.; Senel, S.[Abstract Not Available]Öğe THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA(Bmj Publishing Group, 2022) Gonullu, E.; Kalyoncu, U.; Yagiz, B.; Ates, A.; Kucuksahin, O.; Bilge, S. Yasar; Kanitez, N. A.[Abstract Not Available]Öğe DOSE ESCALATION AND SWITCHING PATTERNS OF ANTI-TNF DRUGS IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE CHART - REVIEW STUDY IN TURKEY(Bmj Publishing Group, 2015) Kalyoncu, U.; Aydin, S. Z.; Dalkilic, E.; Kasifoglu, T.; Kisacik, B.; Pamuk, O. N.; Yilmaz, S.[Abstract Not Available]Öğe EPIDEMIOLOGICAL CHARACTERISTICS OF VIRAL HEPATITIS IN PATIENTS WITH RHEUMATIC DISEASES - IMPLICATIONS FROM TREASURE DATABASE(Bmj Publishing Group, 2022) Ersozlu, D.; Ekici, M.; Coskun, B. N.; Badak, S. O.; Bilgin, E.; Kalyoncu, U.; Yagiz, B.[Abstract Not Available]Öğe THE TRANSITION FROM ACTIVE LESIONS TO STRUCTURAL CHANGES ON SACROILIAC MRI AND ITS ASSOCIATED FACTORS(Bmj Publishing Group, 2023) Kalyoncu, U.; Ayan, G.; Kilic, L.; Atagunduz, P.; Akar, S.; Bilge, N. S. Yasar; Dalkilic, E.[Abstract Not Available]Öğe TREATMENT SATISFACTION, EXPECTATIONS, PATIENT PREFERENCES, AND CHARACTERISTICS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA): TURKISH COHORT RESULTS OF THE SENSE STUDY(Bmj Publishing Group, 2021) Kalyoncu, U.; Kucuk, A.; Sargin, G.; Ozdener, F.; Yolba, S.; Yurttas, B.; Turan, S.[Abstract Not Available]
